AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|
13.5 C
New York
Tuesday, October 20, 2026

Tag: clinical trial

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest

More Than 6,000 Inquiries Since May; Yamo Opens a Registration Site to Help Speed Phase 3 EnrollmentNEW YORK, Oct. 9, 2026 /PRNewswire/ -- Yamo...

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

SUZHOU, China and MÖLNDAL, Sweden, Oct. 7, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to...

Tennessee Oncology Physician Contributes to Landmark Longevity Research

Dr. Yanjun Ma helps uncover genetic and epigenetic clues to extraordinary longevity and cancer resistance in 194-year-old giant tortoiseNASHVILLE, Tenn., Oct. 7, 2026 /PRNewswire/...

Arkayli Biopharma Inc. Receives Study May Proceed Response to IND from FDA and SBIR Grant from NIH to Advance Clinical Development of ARK001 for...

Study May Proceed (SMP) letter is based on IND filing to conduct a Phase 1b Trial of ARK001 in Infants with Infantile Hemangioma (IH)NIH...

Biopharma’s Leapfrog Moment: The Launch of the Digital CMC Consortium

Uniting industry leaders to build the digital standards and infrastructure needed for the future of drug developmentDOVER, Del., Oct. 6, 2026 /PRNewswire/ -- The...

Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

BETHESDA, Md., Oct. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid...

Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility

The new microbiology laboratory and sterility testing suite are designed for GMP drug product applications.This addition is part of the broader Lexington expansion and...

Headlands Research – Summit Portland Celebrates 50 Years of Advancing Alzheimer’s and CNS Clinical Research

Headlands Research site marks five decades in Portland, Oregon, having contributed to clinical trials behind every FDA-approved class of Alzheimer's medication brought to market...

Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer’s Disease

Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biologyTAIPEI,...

Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer’s Disease

Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biologyTAIPEI,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial